Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
How the pipa frog hunts prey by touch
Each of the frog’s eight fingers branches into 16 ultra-sensitive tips, which together function as a fovea—potentially the first demonstration of this type of sensory structure outside of mammals.
How the pipa frog hunts prey by touch
Each of the frog’s eight fingers branches into 16 ultra-sensitive tips, which together function as a fovea—potentially the first demonstration of this type of sensory structure outside of mammals.
Response to ‘Finally, a new route for the magnetic-sense field’
Magnetoreception in Drosophila has much to offer those with an interest in neuroscience.
Response to ‘Finally, a new route for the magnetic-sense field’
Magnetoreception in Drosophila has much to offer those with an interest in neuroscience.
Organoids missing the TSC2 gene form rogue astrocytes; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 28 September.
Organoids missing the TSC2 gene form rogue astrocytes; and more
Here is a roundup of autism-related news and research spotted around the web for the week of 28 September.